CIK 0001070081 · Large accelerated filer
PTC THERAPEUTICS, INC.
Sign in to watch- Ticker
- PTCT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 043416587
- Phone
- 9082227000
- Business address
- 500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ, 07059
- Former names
- PTC THERAPEUTICS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $7,752,145
- in 10 filings, $7.8M under 10b5-1 plans
Net −$7,752,145. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-07-28 | Sollie-Zetlmayer Hege Elisabeth Director | Grant or award · Stock Option (Right to Buy) | +1,738 | 1,738 | ||
| 2026-07-14 | Gravier Pierre CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −3,494 | $80.35 | $281K | 83,986 |
| 2026-07-09 | Smith Mary L. Director | Option exercise 10b5-1 | +10,000 | $42.95 | $430K | 31,813 |
| 2026-07-09 | Smith Mary L. Director | Sale 10b5-1 | −10,000 | $90.00 | $900K | 21,813 |
| 2026-07-09 | Smith Mary L. Director | Option exercise 10b5-1 | +5,834 | $42.95 | $251K | 27,647 |
| 2026-07-09 | Smith Mary L. Director | Sale 10b5-1 | −5,834 | $90.00 | $525K | 21,813 |
| 2026-07-09 | Smith Mary L. Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −10,000 | 0 | ||
| 2026-07-09 | Smith Mary L. Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −5,834 | 0 | ||
| 2026-07-09 | Almstead Neil Gregory CHIEF TECHNICAL OPS OFFICER | Option exercise 10b5-1 | +2,464 | $46.54 | $115K | 62,763 |
| 2026-07-09 | Almstead Neil Gregory CHIEF TECHNICAL OPS OFFICER | Sale 10b5-1 | −2,464 | $90.25 | $222K | 60,299 |
| 2026-07-09 | Almstead Neil Gregory CHIEF TECHNICAL OPS OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −2,464 | 45,036 | ||
| 2026-07-07 | Almstead Neil Gregory CHIEF TECHNICAL OPS OFFICER | Option exercise 10b5-1 | +24,613 | $39.42 | $970K | 84,912 |
| 2026-07-07 | Almstead Neil Gregory CHIEF TECHNICAL OPS OFFICER | Sale 10b5-1 | −3,956 | $87.17 | $345K | 80,956 |
| 2026-07-07 | Almstead Neil Gregory CHIEF TECHNICAL OPS OFFICER | Sale 10b5-1 | −11,369 | $89.03 | $1.0M | 69,587 |
| 2026-07-07 | Almstead Neil Gregory CHIEF TECHNICAL OPS OFFICER | Sale 10b5-1 | −9,288 | $89.44 | $831K | 60,299 |
| 2026-07-07 | Almstead Neil Gregory CHIEF TECHNICAL OPS OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −24,613 | 9,063 | ||
| 2026-07-06 | Boulding Mark Elliott EXEC. VP AND CLO | Option exercise 10b5-1 | +2,266 | $39.42 | $89K | 107,538 |
| 2026-07-06 | Boulding Mark Elliott EXEC. VP AND CLO | Sale 10b5-1 | −313 | $83.10 | $26K | 107,225 |
| 2026-07-06 | Boulding Mark Elliott EXEC. VP AND CLO | Sale 10b5-1 | −833 | $84.41 | $70K | 106,392 |
| 2026-07-06 | Boulding Mark Elliott EXEC. VP AND CLO | Sale 10b5-1 | −519 | $85.84 | $45K | 105,873 |
Page 3 of 25 · 493 trades